On April 1, 2026, Syndax Pharmaceuticals, a biopharmaceutical company listed on Nasdaq with the symbol SNDX, disclosed the granting of inducement awards to eight new employees as part of the 2023 Inducement Plan. These awards allow the purchase of up to 228,500 shares of common stock. The stock options will vest over a span of four years, with the initial 25% becoming available on the first anniversary of the vesting start date. Subsequently, 1/48th of the shares will vest monthly over the following 36 months, contingent upon the employees' continuous service with Syndax up to the respective vesting dates.